PreOmics receives 3.3 million euro for a Series A financing

The start-up based at the IZB that develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry raised 3.3 million euro in series A funding. The round was led by Think. Health Ventures with participation from High-Tech Gründerfonds and business angels. The company intends to use the funds for the continued internationalization of the business and the development of further products. With its technology, the company offers a solution for processing samples for mass spectrometry, which is currently performed using homemade protocols. These processes are often slow, not reproducible, not robust and cannot be automated. PreOmics technology manages to reduce the protocols’ amount of work significantly. PreOmics was founded in August 2016 by Dr. Garwin Pichler and Dr. Nils Kulak. The two scientists worked in the proteomics research group of Prof. Matthias Mann at the Max Planck Institute of Biochemistry.


© PreOmics GmbH